KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fulgent Genetics (FLGT) Other financing activities (2016 - 2025)

Fulgent Genetics' Other financing activities history spans 8 years, with the latest figure at $447000.0 for Q4 2025.

  • For Q4 2025, Other financing activities rose 84.71% year-over-year to $447000.0; the TTM value through Dec 2025 reached $3.0 million, up 4.73%, while the annual FY2025 figure was $3.0 million, 4.73% up from the prior year.
  • Other financing activities for Q4 2025 was $447000.0 at Fulgent Genetics, up from $357000.0 in the prior quarter.
  • Across five years, Other financing activities topped out at $4.1 million in Q4 2021 and bottomed at $39000.0 in Q2 2021.
  • The 5-year median for Other financing activities is $503500.0 (2021), against an average of $902350.0.
  • The largest YoY upside for Other financing activities was 1017.95% in 2022 against a maximum downside of 92.38% in 2022.
  • A 5-year view of Other financing activities shows it stood at $4.1 million in 2021, then crashed by 92.38% to $316000.0 in 2022, then surged by 252.53% to $1.1 million in 2023, then tumbled by 78.28% to $242000.0 in 2024, then surged by 84.71% to $447000.0 in 2025.
  • Per Business Quant, the three most recent readings for FLGT's Other financing activities are $447000.0 (Q4 2025), $357000.0 (Q3 2025), and $345000.0 (Q2 2025).